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Chemical Toxicity of the Granulocyte
by John C. Marsh*
The effect of chemicals, including pharmacologic agents, on blood granulocytes, may be
considered in terms ofthe effects on the function ofmature cells as well as on their number. In
turn, the number of cells can be influenced by chemicals which affect production, destruction
or distribution within the blood.
Neutrophil functions which can be inhibited by chemical agents include chemotaxis,
phagocytosis, degranulation, the metabolic burst related to membrane perturbation and
intracellular killing. Some drugs can influence multiple neutrophil functions.
Neutrophil production may be inhibited by toxic chemicals with a predictable effect, such as
cancer chemotherapeutic drugs, where the effects are dose related, or the process may be
influenced in an unpredictable (idiosyncratic) fashion, occurring only in a small proportion of
patients exposed. Ineffective granulopoiesis with intramedullary death may be seen as a result
of exposure to some drugs, as may increased neutrophil destruction, sometimes via an
immunologic mechanism.
Predictable neutrophil production inhibition by anticancer agents depends on dose, schedule,
route ofadministration, metabolic integrity oforgan systems such as liver and kidney, and the
proliferative state ofthe marrow. For agiven drug, factors which determine neutrophil toxicity
include its mechanism of action, cytotoxic concentration, pharmacokinetics, metabolic and
excretory pathway and target cells in the marrow. The use of assays for clonogenic
hematopoietic precursor cells is allowingcorrelation with more traditional toxicologic methods
and may be helpful in predicting specific hematologic toxicity in man, prior to actual clinical
trials. The agardiffusion chamber assay forneutrophil-macrophage committed colony-forming
cells is particularly useful since it allows in vivo exposure ofthe target cells to the agents being
studied.
Consideration ofthe influence ofchemical agents
on circulating blood granulocytes may be divided
into effects on the function ofthe mature cell and on
the number ofcirculating cells in the blood. In turn,
cell number may be considered from the standpoint
of decreased production by the marrow, increased
destruction, or changes in the ratio of circulating
cells, which are counted, and marginated cells,
which are not.
In this discussion, consideration will be limited to
neutrophilic granulocytes, not only because they
are more numerous than eosinophilic and basophilic
granulocytes, but because much more information
is available about their function, regulation of
production and kinetics.
Neutrophils normally leave the bone marrow as
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mature cells, with a complement of both primary
(azurophilic) and secondary (specific neutrophilic)
granules, which are full of various enzymes which
perform specific tasks. Mature cells are recognized
as such in the blood as either mature polymorpho-
nuclear (PMN) cells or as slightly less mature band
forms. They enter the blood and remain in it with a
half-life ofabout 7 hrand leave it randomly, passing
between capillary endothelial cells into the tissues
where they perform their major task, that ofbeing
the advance guard of phagocytes against invading
microorganisms. Clearly, anything that interferes
with either the normal function of these cells or
their number can predispose the host to infection,
which may be lethal.
Neutrophil Function
In consideringneutrophil function (1), it is impor-
tant to distinguish between studies in vitro, in
71which a drug or chemical is added in varying
concentration to isolated normal cells whose func-
tion is then measured, and in vivo stuides, in which
PMN's are removed from animals or patients who
have been given the drug under study, and whose
function is then compared to that of normal cells.
The latter type of study is more meaningful but,
unfortunately, information of this type is not al-
ways available.
What does a mature PMN do? Among those
functions which can be measured are adherence,
chemotaxis, phagocytosis, degranulation, and a
metabolic burst accompanied byintracellularkilling
of ingested microorganisms.
By adherence is meant the attachment ofcells to
vascular endothelium prior to their leaving the
blood by passage between these same endothelial
cells. The complex changes occurring in diabetes,
as well as in the presence of ethanol, have been
reported to inhibit this process. Epinephrine can
cause a very rapid increase in the concentration of
PMN's in the circulating blood by demargination,
presumably also by interfering with PMN adher-
ence. Histamine, iron oxide, and dextran on the
other hand, appear to enhance the process of
margination, causing a "pseudoneutropenia."
Chemotaxis means the directed movement of
cells in response to a concentration gradient of a
mediator. Among the known chemotactic factors
are bacterial components, those derived from the
complement system, those derived from Hageman
factor activation and those derived from the PMN
itself, including cyclic AMP (cAMP) and certain
prostaglandins. Endotoxin, cellular necrosis,
antigen-antibody complexes, and nonspecific tissue
damage may attract neutrophils by various combi-
nations of these mechanisms.
The process of chemotaxis is most commonly
studied in vitro, using a chamber in which the cells
to be studied are separated from the chemotactic
stimulus by a filter which can then be examined for
the extent of PMN migration through it (2). Its in
vivo counterpart is the skin window (3) in which
coverslips are placed over a skin abrasion, with or
without a bacterial stimulus, and examined quan-
titatively over time for the rate of appearance df
PMN's.
Microtubules within the cell are important in the
chemotactic process. The function of these struc-
tures is inhibited by colchicine, vincristine, and
vinblastine, as well as halothane. Colchicine, as
well as actinomycin D, has also been reported to
interfere with the elaboration of a chemotactic
factor produced by PMN's after they ingest urate
crystals.
The PMN's of colchicine-treated patients, how-
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ever, have been reported to have normal chemotac-
tic responses in vitro, but a decreased response to
inflammatory skin windows. Increased levels of
cAMP inhibit chemotaxis, and the action of hista-
mine, various ,-adrenergic agents, theophylline,
and certain prostaglandins has been explained in
this way. On the other hand, increased levels of
cyclic GMP (cGMP) enhance chemotaxis, and vari-
ous cholinergic drugs, as well as levamisole, are
thought to act in this fashion. High doses ofvitamin
C also enhance chemotaxis.
Several antiinflammatory agents are in vitro
inhibitors ofchemotaxis. These include hydrocorti-
sone, methyl prednisolone, chloroquine, quinine,
and phenylbutazone, while aspirin is without effect.
The relatively high concentrations that were needed
to show this effect, however, raise some question
about the significance of the observation. The
intravenous injection of a large dose of hydrocorti-
sone, however, did inhibit the accumulation of
PMN's at skin windows as well as cause an increase
in the rate ofmarrow input ofPMN's into the blood
(4).
Other inhibitors ofchemotaxis, based on in vitro
studies, include the antibiotics, tetracycline, rifam-
pin, chloramphenicol, and amphotericin B. The
tranquilizer chlorpromazine, penicillamine, ethanol,
heparin, and caffeine have also been identified as
inhibitors.
Phagocytosis is the engulfment of a particle and
its sequestration in an intracellular vacuole. One
can measure both the rate of uptake of particles
over aperiod oftime, orthe number ofparticles per
cell at a specific time. The percentage ofcells which
contain ingested particles can also be measured.
The phagocytic process is also inhibited by cAMP
and enhanced by increased intracellular levels of
cGMP, and therefore is influenced by the same
agents which affect these cyclic nucleotides, men-
tioned above under chemotaxis. Elevated levels of
the sugars galactose and glucose inhibit phagocyto-
sis, thus providing a suggestive explanation for the
increased susceptibility to infection seen in galac-
tosemia as well as the much more common diabetes
mellitus. Colchicine has been reported both to
inhibit and not to influence phagocytosis.
Degranulation is the delivery of the granule
contents ofthe PMN into the phagocytic vacuole or
into the extracellular environment. Intracellular
degranulation is inhibited by colchicine and vinblas-
tine through their effect on microtubules, and by
theophylline, histamine, and ,B-adrenergic agents.
The process is enhanced by cholinergic agents.
Degranulation into the extracellular environment is
inhibited by corticosteroids and chloroquine.
Phagocytosis or, indeed, evenperturbation ofthe
Environmental Health Perspectivesplasma membrane of the cell triggers a burst of
oxygen consumption, increased glucose utilization,
including activation of the hexose monophosphate
shunt, generation of a superoxide anion, which is
important in intracellular killing, and chemilumi-
nescence. Colchicine and vinblastine have been
reported to interfere with the generation of super-
oxide anion.
The antimicrobial systems in the PMN are those
which are oxygen dependent, including that medi-
ated by myeloperoxidase, inhibited by various
sulfonamides and antithyroid agents, and oxygen
independent systems, which include killing medi-
ated by lysozyme, lactoferrin and various cationic
proteins found in the granules.
Lithium carbonate has well defined stimulatory
effects on leukocyte production and is being used to
protect against the neutropenia produced by vari-
ous antineoplastic agents. When the PMN's of
normal volunteers were studied before and after
the ingestion of lithium, they were found to have
normal mobilization to skin windows, nitroblue
tetrazolium reduction (as a measure of superoxide
anion production), normal chemotaxis in a Boyden
chamber to bacterial products, normal phagocyto-
sis, and chemiluminescence but impaired intracellu-
lar killing of ingested Staph. aureus (5). The
importance of this observation relative to the
beneficial effect oflithium on neutrophil production
remains to be determined.
Ethanol has multiple inhibitory effects on the
PMN: not only is there impaired production, but
there is diminished cellular adherence, decreased
chemotaxis in vitro (although skin window tests of
acutely intoxicated patients are normal) and dimin-
ished phagocytosis.
Diabetes has been associated with decreased
PMN adherence, chemotaxis, phagocytosis and
intracellular killing.
Among the defects described in chronic renal
failure and the resulting symptom complex known
as uremia is impaired chemotaxis, but phagocytosis
and intracellular killing of organisms have been
found to be normal in most studies.
Reduced Neutrophil Numbers
(Neutropenia)
In theory, a reduction in the number of circulat-
inggranulocytes inthe blood (6) may come about by
inadequate production in the marrow, excessive
peripheral destruction or utilization, or by a shift in
the circulatinggranulocytes intothe blood marginal
pool, a situation which has been referred to as
"pseudoneutropenia".
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Inadequate production of neutrophils is by far
the most common effect of pharmacologic agents.
Reduced granulocytopoiesis may be predictable or
unpredictable (idiosyncratic).
Predictable neutropenia is the type seen com-
monly with cancer chemotherapeutic agents, which
do not distinguish between normal and cancer cells.
It develops slowly and is dose-dependent. It may
arise from direct stem cell damage, from interrup-
tion of DNA synthesis, the binding or depolymer-
ization of DNA, inhibition of mitosis, or interfer-
ence with protein synthesis. Examples, in addition
to most antineoplastic agents, are chloramphenicol,
rifampin, ristocetin, benzene, ethanol, and nitrous
oxide. We will return to a more detailed consider-
ation of this type of toxicity, particularly with
respect to stem cells, in the discussion below.
Idiosyncratic drug-induced interference with gran-
ulopoiesis may be oftwo types: that which is slow to
develop and dose-dependent and that which ap-
pears to be a hypersensitivity reaction and occurs
rapidly. In the former type, certain types ofpeople
are at increased risk: the old more than the young,
female more than male, and white more than black.
It is thought to be an individual sensitivity of DNA
synthesis, at least with the prototype which is
phenothiazine intoxication. The onset is usually
between two and three weeks after drugingestion,
and the incidence is of the order of 1 in 1000-2000.
Among the drugs implicated in this type ofdelayed
idiosyncratic inhibition of granulocyte production
arephenothiazines, chloramphenicol, acetaminophen
(Tylenol), carbenicillin, butazolidine, propylthiour-
acil, sulfa drugs, and procaine amide.
The rare idiosyncratic neutropenia that appears
to be a hypersensitivity reaction develops within a
few days of beginning drug ingestion. It is usually
associated with prioringestion ofthe drug and with
eosinophilia. Recovery is usually prompt, but may
be slow. Drugs causing it often contain a benzene
ring; they include chloramphenicol, gold salts, phen-
ylbutazone, sulfas, INH, indomethacin, procaine
amide, ampicillin, nitrofurantoin, propylthiouracil,
and chlorothiazide.
Several drugs are associated with what seems to
be ineffective granulopoiesis, that is, an intramed-
ullary death of granulocyte precursors. This is the
picture seen with vitamin B12 or folate deficiency,
and has been described with diphenylhydantoin,
pyrimethamine, ethanol, and chloramphenicol. This
type of neutropenia develops slowly, and is often
dose-dependent and predictable.
Turning to increased granulocyte destruction,
the neutrophil analog of hemolytic anemia, some
drugs cause an immune destruction of granulo-
cytes, mediated through an antibody. This may
73happen within hours if the patient has been pre-
viously exposed to the drug, and within a few days
after initial exposure. The classic drug so impli-
cated is aminopyrine; serum from a sensitized
patient and the drug together will produce neut-
ropenia in a normal patient, but neither is sufficient
when given alone. Rarely, phenylbutazone and
sulfa drugs produce neutropenia through a similar
mechanism. Antibodies which agglutinate neutro-
phils in vitro have been found in some patients with
neutropenia and with a history of ingesting the
following drugs: gold salts, chloroquine, barbitu-
rates, methyldopa, and phenothiazines. The exact
significance of these agglutinins in producing the
neutropenia is uncertain.
Redistribution neutropenia or "pseudoneutro-
penia" is an increase in the marginal granulocyte
pool at the expense ofthe circulating pool, but with
no net change in the total blood granulocyte pool.
Histamine, dextran and iron oxide have all been
reported to effect this redistribution.
Neutropenia Due to Cancer
Chemotherapeutic Agents
As discussed above, neutropenia due to treat-
ment with most antitumor drugs (7) is due to
interference with the production of bone marrow
neutrophils. This may be manifest at several points
in the granulocyte production pathway, but with
the advent of stem cell assays, the effects of many
agents on various blood cell precursors has re-
ceived close attention (8).
The Achilles heel ofcancer chemotherapy is bone
marrow depression, particularly neutropenia with
its attendant risk of infection. Nearly all of the
agents currently in routine clinical use and under
investigation are capable ofproducing this danger-
oussideeffect. Vincristine,bleomycin, L-asparaginase,
and estramustine are among those in which neut-
ropenia is generally mild or absent, and of little
clinical importance.
The potential for the production of neutropenia
by aspecific drugis a function ofthe dose, the route
of administration, the schedule, the metabolic in-
tegrity ofthe host, and the proliferative state ofthe
bone marrow, and its various components.
The depth ofneutropenia and its duration can be
shown to be directly related to the dose of cyclo-
phosphamide invarious groups ofpatients with solid
tumors. Patients with a limited bone marrow re-
serve due to prior destruction by irradiation or
infiltration by tumor are often more sensitive.
The influence of route of administration can be
seen by the fact that doses of 5-fluorouracil or
adriamycin can be given directly into the liver,
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where these drugs are metabolized, in doses that
would cause otherwise prohibitive toxicity.
An example of the importance of schedule is
shown by the experience with a constant dose of
cytosine arabinoside. When the time of a continu-
ous infusion was lengthened from 24 to 48 to 96 hr,
the degree and duration of neutropenia was pro-
gressively prolonged. This is the result of a larger
number of neutrophil precursors in the marrow
coming into contact with this DNA synthesis phase-
specific agent in the longer time period.
The importance of the metabolic integrity of a
specific organ is shown by the fact that adriamycin,
commonly used in lymphomas and in breast, blad-
der, and testicular cancer, may cause lethal toxicity
in a patient with hepatic decompensation in a dose
that would otherwise be well tolerated. In such a
patient, the dose must be decreased by 50 to 75%
because the metabolic degradation of the active
cytotoxic agent is impaired. A similarcaution exists
for the use of methotrexate in the patient with
impaired renal function.
The importance of considering the proliferative
state ofthe bone marrow is shown by the fact that a
specific dose of cyclophosphamide is well tolerated
initially without significant leukopenia, but a sec-
ond identical dose given 12 days later produces a
sharp fall in the level of the circulating blood
neutrophils. This observation can be explained by
the increased sensitivity of the neutrophil precur-
sors, which are rapidly proliferating to compensate
for the cytotoxicity and cell kill caused by the first
dose.
Until recently, our knowledge of bone marrow
toxicity in man resulting from anticancer agents
has been empirically derived from clinical trials
over the last 35 years.
Table 1 contrasts the nadir and recovery time of
blood neutrophils following radiation therapy as
might be given for Stage II Hodgkin's disease, an
alkylating agent such as nitrogen mustard, an
antimetabolite and a nitrosourea. It is clear from
the differences that there are marked variations as
to which precursor cells in the neutrophil series are
primarily affected. The very late toxicity after the
nitrosoureas suggests that they kill an early pre-
cursor cell, while alkylating agents affect more
differentiated precursors. As an oversimplification,
it may be stated that phase-specific agents such as
hydroxyurea or cytosine arabinoside kill only cells
which are in DNA synthesis, while alkylating
agents can have multiple targets, including cells
which are in different phases of the cell cycle.
Nitrosoureas can, in addition, affect very slowly or
nonproliferating multipotent hematopoietic stem
cells.
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What clues are available from clinical observa-
tions to help the physician decide whether a specific
dose of chemotherapy can be given safely? The
integrity of the normal bone marrow can be pre-
sumed to be compromised if neutropenia develops
earlier than a week from a myelotoxic agent, since
the normal marrow granulocyte storage pool should
be able to maintain a normal circulating neutrophil
level for that time, even if the production of
mitotically active cells is completely halted. The
total white blood cell count, if normal, can be
misleading, since the differential count may be
predominately lymphocytes. The absolute number
ofblood neutrophils should be determined. Tests of
bone marrow granulocyte reserve can be used:
these include the neutrophil increment in response
to endotoxin, etiocholanolone or prednisone. These
tests are relatively crude and can indicate the
presence orabsence of agranulocyte storage pool in
the marrow but not whether it is reduced in size.
If there is a significant increase in the ratio of
band to segmented cells in the blood, this indicates
that the marrow granulocyte reserve is inadequate
and that the marrow is still releasing relatively
young cells into the circulation to maintain a normal
blood granulocyte pool.
What factors do we need to know to understand
the potential for bone marrow toxicity of a specific
myelosuppressive drug? They include its biochemi-
cal mechanism ofaction, the effective concentration
required for cell killing, its pharmacokinetics as
determined by volume of distribution, metabolism
and excretion, and the target stem cells in the bone
marrow which are sensitive to its action.
Effects of Antitumor Agents on
Bone Marrow Stem Cells
As discussed in an earlier paper in this sympo-
sium, various assays for hematopoietic stem cells
are available (8). The oldest and perhaps most
significant is that for the multipotent, uncommitted
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cell, which can form colonies of several types of
mature blood cell in the spleen of the irradiated
mouse, the CFU-S (9). This cell normally prolifer-
ates rather slowly (only a small proportion is killed
by exposure to tritiated thymidine), but the rate of
proliferation speeds up if the compartment is re-
duced in size. It meets the definition of a stem cell
in that it is capable of both self-renewal and
differentiation. A severely damaged population of
marrow stem cells proliferates more rapidly than a
less severely damaged one, and there is evidence
(7) that with severe damage (e.g., less than 10%
survivaloftheoriginalcompartment) self-replication
takes priority over differentiation. The CFU-S
compartment seems to be subject to competing
demands for differentiation; i.e., an anemic animal
may be less able to recover normal granulocyte
production than a normal one, because of the
conflicting need for red cell as well as white cell
production.
Since an assay for the uncommitted stem cell
does not exist in man, attention has turned to in
vitro precursor cell assays, which measure clono-
genic cells committed to specific lines of blood cell
formation. Theerythrocyte-committed cells, CFU-E
and BFU-E, are dependent on erythropoietin. The
CFU-C assay (10) measures those cells which can
giverisetogranulocytesandmonocyte-macrophages
in soft agar or methycellulose. Their growth de-
pends on colony-stimulating activity, at least in
vitro, and they are subject to various regulatory
factors which are just becoming clarified.
The granulocytosis produced by lithium has been
reported to be due to an increased release of
colony-stimulating factor (11) and also to an in-
creasedproliferationofpluripotentstemcells(CFU-S)
(12).
Ourlaboratory forthe last several years has been
using a modification of the CFU-C assay, which
utilizes an agar diffusion chamber (ADC) and mea-
sures an agar diffusion chamber precursor cell
(ADCPC) (13). It forms colonies composed ofgran-
ulocytes and macrophages and has two major
advantages over the CFU-C assay: it does not
require a source ofcolony-stimulating activity, and
the drug to be tested can be injected into the
chamber-bearing mouse and thus undergo in vivo
transformation as it interacts with the bone mar-
row clonogenic cells.
We have done two types of assay with this
technique: dose-response experiments in which the
bone marrow is exposed to the drug n situ (only in
the mouse) and then assayed for surviving colony
forming cells); and dose-response experiments in
which the mouse, human, or canine marrow is
exposed to the drug while it is suspended in the
75ADC. The drug is usually injected intravenously
(IV), and after a fixed time (usually 18 hr), the
chamber is transplanted into a normal mouse for
incubation for 7-14 days, depending on the species.
In this way, the sensitivity ofmouse marrow in the
chamber can be compared with that in situ, and
also with marrow from dog and man. Correlations
with toxicology studies in animals and Phase I
studies in man can be made. It should be possible
then, to predict the potential for the production of
neutropenia by a new drug in humans without ever
exposing patients to it. Curves relating stem-cell
survival to drug dose are of two major types,
although sometimes complex curves are seen.
The first type is an exponential curve, reflecting
first-order kinetics of clonogenic cell kill. This
means that the population of colony- forming cells
in the marrow is killed in afixed proportion for each
increment of a drug over the range studied, and
that the dose-survival curve is a straight line when
plotted on semi-logarithmic paper. Doses which
produce a specific cell survival (D37 = that dose
required to kill 63% of the cells) can be calculated
from the exponential portion ofthe curve and these
doses compared for different species. When we
studied adriamycin (Fig. 1), we found similar sen-
sitivities for mouse marrow in situ, in the chamber,
and human marrow (D37 values of8, 8, and 9 mg/kg)
but dog marrow was much more sensitive (3.5
mg/kg)(14). The dog is known from toxicologic
studies to be the most sensitive ofthese species to
adriamycin, whose limiting toxicity is granulocyt-
openia. The adriamycin derivative, AD-32, has a
similar order of marrow colony-forming cell sensi-
tivity, although human cells are relatively more
sensitive than to adriamycin. It was predicted that
granulocytopenia would be the limiting clinical
toxicity for AD-32 also; such, indeed, is the case
(15). Carminomycin, a Russian anthracycline de-
rivative, has an exponential dose-survival curve,
while the anthracycline marcellomycin, which has
no leukocyte toxicity in mice, has virtually a flat
dose-survival curve.
Other drugs with exponential dose-survival
curves for ADCPC include vinblastine, cyclophos-
phamide, 5-fluorouracil, cis-platinum, and pyrazo-
furin. There are, however, definite differences in
the slopes of the curves for different species, and
the species sensitivities vary from drug to drug;
they are not predictable (16).
The other major type of dose-survival curve is
the plateau, in which only a limited proportion of
colony-forming cells is killed, regardless ofthe dose
ofdruggiven (Fig. 2). This is due to the drugkilling
cells only in a certain phase ofthe cell cycle, and, in






















10 20 30 40
DOSE ADRIAMYCIN (mg/kg)
FIGURE 1. Dose-survival curves ofbone marrow agardiffusion
chamber precursor cells from different species 18 hr after
adriamycin.
delay or block in passing through the cycle. The
location of the plateau is determined also by the
pharmacokinetics of the drug, i.e., how long the
population is exposed to a cytotoxic concentration
of drug. Since this is the same when the marrows
from different species are exposed in the chamber,
a true picture of comparative species sensitivities
can be obtained. Drugs which produce plateau
dose-survival curves include the antifolates metho-
trexate, triazinate (Baker's antifol), a trimethoxy-
quinazoline derivative about to enter clinical trial,
cytosine arabinoside (17), and 5-azacytidine. Es-
tramustine produces a plateau for dog and human
ADCPC, but an exponential curve for mouse mar-
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FIGURE 2. Dose-survival curves ofbone marrow agar diffusion
chamber precursor cells from different species 18 hr after
methotrexate.
usually slight, but again, are not consistent or
predictable.
The effect of two-drug combinations can also be
tested in this system. A combination ofmethotrex-
ate and 5-fluorouracil is of current clinical interest
and appears to be synergistic in killing some kinds
of tumors. Naturally, the therapeutic index de-
pends on whether or not this combination also kills
marrow colony-forming cells synergistically as well.
Some preliminary data with marrow from all three
species suggests that it does not. Likewise, it has
been shown that pretreatment ofmice with allopur-
inol will protect mice from 5-FU lethality (18). We
have observed that allopurinol protects marrow
ADCPC in mice from this drug, which may explain
at least part of the toxicologic effect (19).
In conclusion, the leukocyte-committed colony
forming cell (ADCPC or CFU-C) is probably the
most relevant population for the study of hematol-
ogical toxicity in man, since leukopenia is the most
potentially lethal complication of such toxicity. It
can be studied serially over a period of time in the
blood or marrow, as well as evaluated for sensitiv-
ity to specific drugs in specific individuals. The
assay is potentially of value in predicting the
likelihood that a given drug will produce significant
neutropenia in man without the necessity for clini-
cal trial. In combination with assays oftumor stem
cell drug sensitivity, it may be possible to design
optimal chemotherapy for cancer patients in a much
more rational fashion than hitherto has been the
case.
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